Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2620-2635

  Buzdar, A ^a   Howell, A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CORTISONE ACETATE; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; GLUCOCORTICOID; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; VOROZOLE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HIRSUTISM; HUMAN; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

ANDROSTADIENES; ANDROSTENEDIONE; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FADROZOLE; FEMALE; HEADACHE; HUMANS; NAUSEA; NITRILES; TREATMENT OUTCOME; TRIAZOLES; VOMITING;

EID: 0034802910     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. On the treatment of inoperable cases of carcinoma of the mamma; suggestions for a new method of treatment with illustrative cases
2. Alternative mechanisms of action of anti-oestrogens
3. Induction of transforming growth factor β 1 in human breast cancer in vivo following tamoxifen treatment
4. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression
5. Metastatic breast cancer
6. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature Phase III trials
7. The control of breast cancer: The role of tamoxifen
8. Efficacy of tamoxifen as treatment of breast cancer
9. Tamoxifen for early breast cancer: An overview of the randomized trials
10. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma
11. Aromatase inhibitors and their use in the adjuvant setting
12. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer
13. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer
14. Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: Mechanism of action and role in management
15. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer
16. Letrozole. A review of its use in postmenopausal women with advanced breast cancer
17. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor
18. Hormonal therapy of breast cancer
19. A review of the newer aromatase inhibitors in the management of metastatic breast cancer
20. Aromatase inhibitors in the treatment of postmenopausal breast cancer
21. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer
22. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
23. New endocrine therapies for breast cancer
24. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A Phase III prospective randomized cross over trial of second-line hormonal treatment (SAKK 20/90)
25. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
26. Novel irreversible aromatase inhibitors
27. Specificity of low-dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor
28. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer
29. Arimidex. A new oral, once-a-day aromatase inhibitor
30. "Arimidex." An overview of a new selective nonsteroidal aromatase inhibitor
31. Arimidex. A potent and selective fourth-generation aromatase inhibitor
32. "Arimidex" (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers
33. "Arimidex" (ZD1033). A Phase I study of a new, selective orally active aromatase inhibitor in postmenopausal women with advanced breast cancer
34. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women
35. Pharmacology of nonsteroidal aromatase inhibitors
36. Letrozole, a new oral nonsteroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study
37. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer
38. Letrozole (CGS 20267). A Phase I study of a new potent oral aromatase inhibitor of breast cancer
39. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
40. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen
41. Phase II study of vorozole (R83842), a new non-steroidal aromatase inhibitor, in advanced breast cancer
42. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer
43. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
44. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients
45. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer
46. 6-Methyleneandrosta-1, 4-diene-3, 17-dione (FCE 24304): A new irreversible aromatase inhibitor
47. Influence of anastrozole ("Arimidex"), a selective, nonsteroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in post-menopausal women with breast cancer
48. Letrozole suppresses estrogen levels in postmenopausal breast cancer patients more completely than anastrozole
49. Letrozole achieves more complete inhibition of whole body aromatisation than anastrozole
50. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer
51. 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer
52. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor in postmenopausal breast cancer patients: A Phase I study
53. Multicenter Phase II trial of exemestane as hormonal therapy of postmenopausal women with breast cancer
54. A randomised trial comparing two doses of the new selective aromatase inhibitor ("Arimidex") with megestrol acetate in postmenopausal women with advanced breast cancer
55. A Phase III trial comparing anastrozole (1 and 10mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer
56. Clarification of anastrozole/megestrol acetate trial program design
57. Assessment of response to therapy in advanced breast cancer
58. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two Phase III trials
59. Arimidex (anastrozole) - Effective in advanced breast cancer (ABC) patients with visceral and liver metastases
60. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
61. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
62. Evaluation of the cancer patient and the response to treatment
63. Letrozole. Updated duration of response
64. Letrozole. Which dose to be used?
65. Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
66. Randomized Phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
67. Rivizor versus aminoglutethimide (AG) in the second-line endocrine treatment of postmenopausal patients with advanced breast cancer (ABC) following tamoxifen failure
68. A Phase III trial comparing vorozole (Rivizor) versus aminoglutethimide in the treatment of advanced postmenopausal breast cancer
69. Fadrozole HCl (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma
70. Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen
71. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a Phase III randomized double-blind study
72. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or Arimidex randomized group efficacy and tolerability study
73. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
74. Preliminary results of two multi-center trials comparing the efficacy and tolerability of "Arimidex" (anastrozole) and tamoxifen in postmenopausal women with advanced breast cancer
75. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women - Combined analysis of two identically designed multicenter trials
76. Anastrozole vs. tamoxifen in hormonodependent advanced breast cancer. A Phase II randomized trial
77. Letrozole (Femara) versus tamoxifen: Preliminary data of a first-line clinical trial in postmenopausal women with locally advanced or metastatic breast cancer
78. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer
79. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): Results of a randomized Phase II trial
80. The third-generation nonsteroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
81. Risks versus benefits in the clinical application of aromatase inhibitors
82. Aromatase inhibitors in the treatment and prevention of breast cancer
83. Role of aromatase inhibitors in advanced breast cancer
84. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A Phase II multicentre, multinational study
85. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: A Phase II study
86. "Arimidex" as neoadjuvant therapy causes large reductions in tumor volume in postmenopausal women with large operable breast cancers
87. Effects of neoadjuvant treatment with the aromatase inhibitor, anastrozole ("Arimidex") on peripheral and in situ estrogen synthesis and uptake by breast tissue in postmenopausal women
88. Comparison of the effects of neoadjuvant "Arimidex" (anastrozole) on plasma and intratumor tissue estrogen levels in postmenopausal breast cancer patients
89. Effects of letrozole as primary medical therapy on in situ estrogen synthesis and endogenous levels within the breast
90. Letrozole as primary medical therapy for locally advanced and large operable breast cancer
91. Neo-adjuvant treatment of postmenopausal breast cancer patients with letrozole (Femara): A randomized study versus tamoxifen
92. Use of aromatase inhibitors in the adjuvant treatment of breast cancer
93. "Arimidex" tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
94. Aromatase inhibitors and their future role in postmenopausal women with early breast cancer
95. Anastrozole shows evidence of activity in postmenopausal patients who responded or stabilised on formestane therapy
96. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A Phase II trial